Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)
About this study
The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and muscle capillary blood volume, improves vascular function in the larger conduit vessels, and enhances insulin's metabolic action in humans with Type 2 diabetes. Subjects will be randomized to one of the three groups: exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 16 weeks of intervention.
- Condition
- Type2 Diabetes
- Tested
- Exercise, Liraglutide
- Sponsor
- University of Virginia
Who can join
- Age
- 21 to 60 years
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 8
- Minimum age: 21 years
- Maximum age: 60 years
- Study condition: Type2 Diabetes
- Age 21-60
- A1C ≤ 8.5%
- Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
- On stable dose of oral hypoglycemic agents \>4 months
- On stable dose of other medications for \>4 months
Exclusion 10
- Taking Insulin
- Smoking presently or in the past 6 months
- BP \>160/90
- BMI \>35
- Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome
- History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.
- Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease
- Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI).
- Pregnant or breastfeeding.
- Known hypersensitivity to perflutren (contained in Definity)
Where
1 site, 1 recruiting
University of Virginia
Charlottesville, Virginia, United States
Contact
-
Lee Hartline, MEd
434-924-5247 lmh9d@virginia.eud
-
Linda Jahn, RN, MEd
434-924-1134 las6e@virginia.edu
Potential match only. Final eligibility is determined by the study team.